Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1998 1
1999 1
2010 1
2011 1
2020 1
2021 2
2022 2
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Testicular Lymphoma"
Page 1
Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management.
Nguyen HTK, Terao MA, Green DM, Pui CH, Inaba H. Nguyen HTK, et al. Cancer. 2021 Sep 1;127(17):3067-3081. doi: 10.1002/cncr.33609. Epub 2021 May 25. Cancer. 2021. PMID: 34031876 Free PMC article. Review.
However, the management of testicular leukemia is not well described in the recent literature and remains relevant in low- and middle-income countries where testicular relapse is still experienced. ...For refractory or early-relapse testicular leukemia …
However, the management of testicular leukemia is not well described in the recent literature and remains relevant in low- and middle …
Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.
Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X, Xie Z, Qiao X, Jiang H, Shao J, Yang F, Ren H, Cao Q, Qian J, Zhang J, An K, Wang J, Luo C, Liang H, Miao Y, Ma Y, Wang X, Ding L, Song L, He H, Shi W, Xiao P, Yang X, Yang J, Li W, Zhu Y, Wang N, Gu L, Chen Q, Tang J, Yang JJ, Cheng C, Leung W, Chen J, Lu J, Li B, Pui CH. Wang T, et al. J Clin Oncol. 2023 Mar 20;41(9):1670-1683. doi: 10.1200/JCO.22.01214. Epub 2022 Nov 8. J Clin Oncol. 2023. PMID: 36346962 Free PMC article. Clinical Trial.
RESULTS: Complete remission was achieved in 99.0% of the 194 patients with refractory leukemia or hematologic relapse, all negative for minimal residual disease. ...CONCLUSION: CD19-/CD22-CAR T-cell therapy achieved relatively durable remission in children with relapsed or …
RESULTS: Complete remission was achieved in 99.0% of the 194 patients with refractory leukemia or hematologic relapse, all negative f …
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma.
Conconi A, Chiappella A, Ferreri AJM, Stathis A, Botto B, Sassone M, Gaidano G, Balzarotti M, Merli F, Tucci A, Vanazzi A, Tani M, Bruna R, Orsucci L, Cabras MG, Celli M, Annibali O, Liberati AM, Zanni M, Ghiggi C, Pisani F, Pinotti G, Dore F, Esposito F, Pirosa MC, Cesaretti M, Bonomini L, Vitolo U, Zucca E. Conconi A, et al. Blood Adv. 2024 Mar 26;8(6):1541-1549. doi: 10.1182/bloodadvances.2023011251. Blood Adv. 2024. PMID: 38181782 Free PMC article. Clinical Trial.
Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by high risk of contralateral testis and central nervous system (CNS) relapse. ...In 4 cases, the relapse occurred >6 years after treatment. Causes of death were lymphoma (n = 4), seco …
Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by high risk of contralateral testis and central nervo …
Testicular Plasmablastic Lymphoma in an HIV-Negative Patient: A Rare Case Presentation.
Nwanwene K, Khan NAJ, Alsharedi M. Nwanwene K, et al. J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211017423. doi: 10.1177/23247096211017423. J Investig Med High Impact Case Rep. 2021. PMID: 34032157 Free PMC article.
Plasmablastic lymphoma (PBL) is a very rare disease and it is usually considered a human immunodeficiency virus (HIV)-related B-cell lymphoma that carries a poor prognosis. ...Therapeutic regimens like dose-adjusted etoposide, vincristine, doxorubicin, cyclophospham …
Plasmablastic lymphoma (PBL) is a very rare disease and it is usually considered a human immunodeficiency virus (HIV)-related B-cell …
Adverse events and efficacy of second-round CAR-T cell therapy in relapsed pediatric B-ALL.
Ji Q, Wu X, Zhang Y, Zeng L, Dong Y, Liu R, Li B, Bai Z, Hu S, Lu J, Wu S. Ji Q, et al. Eur J Haematol. 2024 Jan;112(1):75-82. doi: 10.1111/ejh.14092. Epub 2023 Aug 30. Eur J Haematol. 2024. PMID: 37649264
OBJECTIVE: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment approach for pediatric patients suffering from relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, there was a paucity of data on the challenges associated with se …
OBJECTIVE: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment approach for pediatric patients suffering from relap …
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30(+) lymphoma: a phase 1 study.
Grover NS, Hucks G, Riches ML, Ivanova A, Moore DT, Shea TC, Seegars MB, Armistead PM, Kasow KA, Beaven AW, Dittus C, Coghill JM, Jamieson KJ, Vincent BG, Wood WA, Cheng C, Morrison JK, West J, Cavallo T, Dotti G, Serody JS, Savoldo B. Grover NS, et al. Lancet Haematol. 2024 May;11(5):e358-e367. doi: 10.1016/S2352-3026(24)00064-4. Epub 2024 Mar 28. Lancet Haematol. 2024. PMID: 38555923 Clinical Trial.
Patients aged 3 years and older, with classical Hodgkin lymphoma or non-Hodgkin lymphoma with CD30(+) disease documented by immunohistochemistry, and a Karnofsky performance score of more than 60% planned for autologous HSCT were eligible if they were considered hig …
Patients aged 3 years and older, with classical Hodgkin lymphoma or non-Hodgkin lymphoma with CD30(+) disease documented by im …
Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity.
Zhang N, Shao J, Li H, Zhu J, Xia M, Chen K, Jiang H. Zhang N, et al. J Immunother. 2022 Nov-Dec 01;45(9):396-406. doi: 10.1097/CJI.0000000000000437. Epub 2022 Aug 29. J Immunother. 2022. PMID: 36018262 Free PMC article.
Chimeric antigen receptor T cell (CAR-T) therapy has breakthrough potential for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). However, because of the risk for neurotoxicity, trials usually exclude patients with central nervous system leukemia (CNSL) or acti …
Chimeric antigen receptor T cell (CAR-T) therapy has breakthrough potential for relapsed/refractory (R/R) acute lymphoblastic leukemi …
Gallium nitrate: the second metal with clinical activity.
Foster BJ, Clagett-Carr K, Hoth D, Leyland-Jones B. Foster BJ, et al. Cancer Treat Rep. 1986 Nov;70(11):1311-9. Cancer Treat Rep. 1986. PMID: 3533251 Review.
In limited phase II evaluation, the drug has shown antitumor activity in patients with either refractory lymphomas or small cell lung carcinoma, with total objective response rates of 28% and 11%, respectively. ...Some are already ongoing in patients with genitourin …
In limited phase II evaluation, the drug has shown antitumor activity in patients with either refractory lymphomas or small ce …
Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia.
Rubinstein JD, Krupski C, Nelson AS, O'Brien MM, Davies SM, Phillips CL. Rubinstein JD, et al. Biol Blood Marrow Transplant. 2020 Nov;26(11):e280-e285. doi: 10.1016/j.bbmt.2020.07.036. Epub 2020 Aug 2. Biol Blood Marrow Transplant. 2020. PMID: 32755637 Free article.
Autologous CD19-directed chimeric antigen receptor T lymphocyte (CAR-T) therapy is an approved and effective treatment for the management of patients with refractory and multiply relapsed B cell precursor acute lymphoblastic leukemia (B-ALL). ...Six patients had isolated c …
Autologous CD19-directed chimeric antigen receptor T lymphocyte (CAR-T) therapy is an approved and effective treatment for the management of …
Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.
Cheson BD, Vena DA, Barrett J, Freidlin B. Cheson BD, et al. J Clin Oncol. 1999 Aug;17(8):2454-60. doi: 10.1200/JCO.1999.17.8.2454. J Clin Oncol. 1999. PMID: 10561309
PATIENTS AND METHODS: We reviewed the long-term follow-up data for 2,014 patients treated on National Cancer Institute Group C protocols with fludarabine for relapsed and refractory CLL and with DCF and CdA for HCL using a Second Cancer Report. ...RESULTS: Median follow-up …
PATIENTS AND METHODS: We reviewed the long-term follow-up data for 2,014 patients treated on National Cancer Institute Group C protocols wit …
13 results